MÃ¡rcia Waddington Cruz

List of Publications by Year
in descending order

35 papers	5,027 citations	489802 18 h-index	406436 35 g-index
35 all docs	35 docs citations	35 times ranked	4154 citing authors

#	Article	IF	Citations
1	Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 175-183.	1.4	7
2	A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 228-236.	1.4	9
3	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	4.9	93
4	Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurology and Therapy, 2021, 10, 375-389.	1.4	34
5	Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurology and Therapy, 2021, 10, 753-766.	1.4	14
6	Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Journal of the Peripheral Nervous System, 2021, 26, 160-166.	1.4	6
7	Posicionamento sobre DiagnÃ³stico e Tratamento da Amiloidose CardÃaca â€“ 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 561-598.	0.3	35
8	Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center. Arquivos De Neuro-Psiquiatria, 2021, , .	0.3	1
9	Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. Journal of Neurology, 2020, 267, 1070-1079.	1.8	20
10	Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Muscle and Nerve, 2020, 62, 509-515.	1.0	9
11	A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 179.	1.2	33
12	Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5ÂYears. Neurology and Therapy, 2020, 9, 105-115.	1.4	17
13	Albumin/creatinine (uACR) and protein/creatinine (uPCR) ratios in spot urine samples can be used to evaluate albuminuria and proteinuria in hereditary transthyretin amyloidosis patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 41-42.	1.4	1
14	Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurology, 2019, 19, 146.	0.8	32
15	Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology, 2019, 12, 701-711.	1.3	25
16	Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 10-14.	1.4	26
17	Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry. Journal of the Neurological Sciences, 2019, 403, 1-6.	0.3	18
18	Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS). Arquivos De Neuro-Psiquiatria, 2019, 77, 96-100.	0.3	18

#	Article	IF	Citations
19	Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet Journal of Rare Diseases, 2019, 14, 34.	1.2	38
20	Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arquivos De Neuro-Psiquiatria, 2018, 76, 609-621.	0.3	16
21	Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy. Journal of the Neurological Sciences, 2018, 394, 78-83.	0.3	8
22	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 22-31.	13.9	1,000
23	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	13.9	1,558
24	Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis. Blood, 2018, 132, 498-498.	0.6	2
25	The demographic, genetic, and clinical characteristics of Latin American subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 107-108.	1.4	6
26	Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 111-112.	1.4	9
27	The demographic, genetic, and clinical characteristics of Brazilian subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 103-104.	1.4	8
28	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	59
29	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	1.2	338
30	Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 178-183.	1.4	84
31	Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet Journal of Rare Diseases, 2015, 10, 109.	1.2	246
32	A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis. Neurology and Therapy, 2015, 4, 61-79.	1.4	59
33	Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases, 2013, 8, 31.	1.2	525
34	Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 65-67.	1.4	15
35	Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology, 2012, 79, 785-792.	1.5	658